NCT05328752 - Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Interventions

DRUG

XXB750

DRUG

Placebo

Trial Locations (4)

Jacksonville Ctr for Clin Rea Main Centre, Jacksonville

Nature Coast Clinical Research LLC, Inverness

Fairview Health Services ., Saint Paul

Novartis Investigative Site, Groningen